IL312533A - Novel auristatin analogs and immunoconjugates thereof - Google Patents

Novel auristatin analogs and immunoconjugates thereof

Info

Publication number
IL312533A
IL312533A IL312533A IL31253324A IL312533A IL 312533 A IL312533 A IL 312533A IL 312533 A IL312533 A IL 312533A IL 31253324 A IL31253324 A IL 31253324A IL 312533 A IL312533 A IL 312533A
Authority
IL
Israel
Prior art keywords
int
compound
immunoconjugate
ono
methyl
Prior art date
Application number
IL312533A
Other languages
English (en)
Hebrew (he)
Inventor
Hui LI Richard
Jun Lee Dong
Original Assignee
Adcentrx Therapeutics Inc
Hui LI Richard
Jun Lee Dong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc, Hui LI Richard, Jun Lee Dong filed Critical Adcentrx Therapeutics Inc
Publication of IL312533A publication Critical patent/IL312533A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL312533A 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof IL312533A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US202163295476P 2021-12-30 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
IL312533A true IL312533A (en) 2024-07-01

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312533A IL312533A (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Country Status (10)

Country Link
US (1) US20260131016A1 (enExample)
EP (1) EP4426714A4 (enExample)
JP (1) JP2024540402A (enExample)
KR (1) KR20240110584A (enExample)
AU (1) AU2022380491A1 (enExample)
CA (1) CA3236944A1 (enExample)
IL (1) IL312533A (enExample)
MX (1) MX2024005342A (enExample)
TW (1) TW202334176A (enExample)
WO (1) WO2023081230A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
KR20240110584A (ko) 2024-07-15
EP4426714A1 (en) 2024-09-11
TW202334176A (zh) 2023-09-01
AU2022380491A1 (en) 2024-05-30
MX2024005342A (es) 2024-09-27
WO2023081230A1 (en) 2023-05-11
CA3236944A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
US20260131016A1 (en) 2026-05-14
JP2024540402A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
AU2020263231B2 (en) Camptothecin derivatives
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
CN106459055B (zh) 双功能细胞毒类药剂
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
ES2867749T3 (es) Conectores y su aplicación con respecto a los CAF
CA3027178A1 (en) Anti-egfr antibody drug conjugates
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
CN121574085A (zh) 缀合物及其用途
JP2025518554A (ja) リガンド薬物複合体及びその使用
AU2022422015A1 (en) Novel auristatin analogs and immunoconjugates thereof
AU2022380491A1 (en) Novel auristatin analogs and immunoconjugates thereof
EP4471005A1 (en) Conjugate and use thereof
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
HK40117241A (en) Novel auristatin analogs and immunoconjugates thereof
HK40115429A (en) Novel auristatin analogs and immunoconjugates thereof
CA3137125C (en) Camptothecin derivatives
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors
EP4633738A1 (en) Cytotoxic compounds
WO2024127333A1 (en) Cytotoxic compounds
CN121358743A (zh) 用于治疗或预防癌症的喜树碱衍生物及其抗体药物偶联物
HK1233252A1 (en) Bifunctional cytotoxic agents